6.15.23-STEX-CA-Bloomer-Tech

SPEAKER: All right. Thank you. Next up we have Bloomer Tech. It's digital transformation putting women's health at the forefront.

ACEIL HALABY: Hello.

SPEAKER: The big one.

ACEIL HALABY: Hi. Thank you, everyone. So my name is Aceil. I'm founder and COO of Bloomer Tech. My co-founder and I graduated from the Computational Cardiovascular Research Group at the MIT Collective Intelligence Center.

And so I'm going to talk about how we're eradicating disparities in health care using novel digital biomarkers. And what you're seeing up here is a sneak peek into our patented sensing technology, which is creating one of its kind database that feeds into our biomarker engine and AI models. OK.

So today, heart disease and stroke are the leading causes of disability and mortality around the world. And the databases that we use for clinical decision making and treatment design represent only a fraction of our population. So this is a main reason why it's harder to detect, diagnose, and treat underrepresented populations. The largest subgroup being women, which is half our world. Even more dire is the advent of AI in health care, which is predicated on these inequitable data sets and really only promises to exacerbate the problem, which in the US alone one quantified variable, if you will, is the $162 billion economic burden annually, which is growing.

So today there's been key opinion leaders who have been building a good body of evidence for the past 30 years showing how we can optimize care for women. And the FDA is supporting this with a structure for evaluating underperforming devices. Bloomer Tech is already addressing this.

So we've designed a platform that connects an augmented garment to a biomarker engine. And using our natural augmented garment, we passively and continuously collect medical grade data from her torso, chest, and lungs via Bluetooth we connect to a mobile app where we collect additional data like electronic patient reported outcomes. And from this data, we extract millions of biomarker data, including p-wave and soon thoracic impedance and potassium levels. Now, as we build our multi-omic data set, we really will be able to generate novel digital biomarkers that give insights across the continuum of care rather than blood tests that take a snapshot in time.

We've garnered organic inbound interest from pharma where we provided data services to explore new indications for existing drugs. And we're building on this success by getting on path to secure an FDA clearance for ECG monitoring. This is a very straightforward regulatory strategy that really will unlock large opportunities for our biomarker engine. So to take one example from one of the key opinion leaders that we work with, their women's heart center receives 18,500 patients per month. 6,600 of which are new and a lot of them require ECG monitoring.

If you take the average $250 reimbursement for a monitoring session, that's over $1 million opportunity in that one hospital per month. But there are over 300 of these women's heart centers around the US. And we're partnering with them to deploy female-specific solutions.

And there's more. So we have a really large roadmap across the continuum of care, where we will be releasing novel digital biomarkers that, again, optimize how quickly we diagnose and target treatments for women. And as you can see, we've combined many industries. So we're always looking for partners that want to create change in this space for women's health and for the underrepresented populations. So thank you. And I can demo the product at our booth later.